Anastasiia Melnikova

Based in:

London, United Kingdom

Anastasiia Melnikova

Based in:

London, United Kingdom

A. Melnikova

From Molecules

From Molecules

to Market Strategy


to Market Strategy


Translational biotech research

Market & investment analysis

Strategic insight generation

Venture & business strategy

Stakeholder-driven innovation

Let’s work together

Let’s work together

Icon
Icon

Let’s work together

Icon

Meet biotech

(©19-25)

(51.5072' N 0.1276' W)

Biotech is not only about labs and papers - it’s about vision, Style, and creating market-ready solutions.
Biotech is not only about labs and papers - it’s about vision, Style, and creating market-ready solutions.
Biotech is not only about labs and papers - it’s about vision, Style, and creating market-ready solutions.
About Image
About Image
About Image

Hi, I’m Anastasiia

Born in Moscow and raised on curiosity.


Fascinated by innovation since childhood, I’ve

always loved blending science with business - and trained in professional sports along the way (boxing included).


I’ve recently crossed to the dark side - the commercial one - like many scientists before me, pursuing impact beyond the lab.

"If Elle Woods can win a trial in pink heels, I can turn scars into a $100M biotech strategy."

"If Elle Woods can win a trial in pink heels, I can turn scars into a $100M biotech strategy."

View my work

View my work

Icon
Icon

View my work

Icon
Pattren
Pattren
Pattren

Experience

Experience

that

Drives

results

(01)

King’s College

Icon

(02)

 MSU

Icon

(03)

Achievements

Icon

See LinkedIn

See LinkedIn

Icon
Icon
Icon

Because even unpopular

diseases deserve a Power Pitch.

DermaNova-29a™ - Innovative Exosome-Based Therapy for aggressive scarring, also known as keloids. From preclinical concept to First-in-Human trials.


Built a novel cooling-device design and a complete manufacturing and regulatory pathway for SA launch and UK/EU expansion.


Validated with global stakeholders across 3 continents, opening a new biotech hub in Africa.


Delivered a competitive and financial analysis projecting 5–10× ROI and $75–100 M exit, defining a sharp competitive edge, clear FTO/IP map, and an investor-ready venture in regenerative aesthetics.


Top of cohort (88/100)

Therapy (AMTP)

Financial Analysis

Stakeholders

Regulatory (Windsor framework)

Competitive Edge

Novel Device

Pitch Ready

Potential Acquirers (Galderma, AbbVie, L’Oréal Dermatology)

Icon

12 months

Service Image

(01)

King’s College

Icon

(02)

 MSU

Icon

(03)

Achievements

Icon

See LinkedIn

See LinkedIn

Icon
Icon
Icon

Because even unpopular

diseases deserve a Power Pitch.

DermaNova-29a™ - Innovative Exosome-Based Therapy for aggressive scarring, also known as keloids. From preclinical concept to First-in-Human trials.


Built a novel cooling-device design and a complete manufacturing and regulatory pathway for SA launch and UK/EU expansion.


Validated with global stakeholders across 3 continents, opening a new biotech hub in Africa.


Delivered a competitive and financial analysis projecting 5–10× ROI and $75–100 M exit, defining a sharp competitive edge, clear FTO/IP map, and an investor-ready venture in regenerative aesthetics.


Top of the cohort received recommendations

Therapy (AMTP)

Financial Analysis

Stakeholders

Regulatory (Windsor framework)

Competitive Edge

Novel Device

Pitch Ready

Potential Acquirers (Galderma, AbbVie, L’Oréal Dermatology)

Icon

12 months

Service Image

(01)

King’s College

Icon

(02)

 MSU

Icon

(03)

Achievements

Icon

See LinkedIn

Icon
Icon

Because even unpopular

diseases deserve a Power Pitch.

DermaNova-29a™ - Innovative Exosome-Based Therapy for aggressive scarring, also known as keloids. From preclinical concept to First-in-Human trials.


Built a novel cooling-device design and a complete manufacturing and regulatory pathway for SA launch and UK/EU expansion.


Validated with global stakeholders across 3 continents, opening a new biotech hub in Africa.


Delivered a competitive and financial analysis projecting 5–10× ROI and $75–100 M exit, defining a sharp competitive edge, clear FTO/IP map, and an investor-ready venture in regenerative aesthetics.


Top of cohort (88/100)

Therapy (AMTP)

Financial Analysis

Stakeholders

Regulatory (Windsor framework)

Competitive Edge

Novel Device

Pitch Ready

Potential Acquirers (Galderma, AbbVie, L’Oréal Dermatology)

Icon

12 months

Service Image

Trusted by the visionaries

Turning science into stories, data into strategy, and ideas into market impact.

0+

hours in the lab

BG Image

My track record

Metrics

that

Prove

value

Know more about me

Know more about me

Icon
Icon

Know more about me

Icon
0+

interviews with patients, physicians, suppliers, investors

0+

interviews with patients, physicians, suppliers, investors

0+

interviews with patients, physicians, suppliers, investors

0+

academic and business projects delivered

0+

academic and business projects delivered

0+

academic and business projects delivered

0

years of sport - discipline in motion.

0

years of sport - discipline in motion.

0

years of sport - discipline in motion.

0+

lab hours - precision, patience, and molecular mastery

0+

lab hours - precision, patience, and molecular mastery

0+

lab hours - precision, patience, and molecular mastery

Vector

Proof in every project

Collaboration

&

Global experience

Global experience

Global experience

Collaboration

Global by experience, collaborative by nature.

Lived and studied across three countries the UK, China & Russia.

Worked with teams from the USA, Europe, Australia & Asia.

Lived and studied across three countries the UK, China & Russia.

Worked with teams from the USA, Europe, Australia & Asia.

Anastasiia Melnikova

See LinkedIn

Avatar
Avatar
BG Image
BG Image
BG Image

Mindset

Mindset

Built on resilience, rhythm, and teamwork shaped by years of synchronised swimming and boxing.

Origin matters

Experience across academia, consulting, accelerators.

BG Image
BG Image
BG Image

Kickstart Global

Tailored outreach to investor portfolios. Initiated sponsorship talks with HSBC Innovation Banking.

0+

investors engaged for the Google HQ showcase.

0+

investors engaged for the Google HQ showcase.

0+

investors engaged for the Google HQ showcase.

Kickstart

the UK’s largest cross-university accelerator.

BG Image

Contact me

Feel

Feel

Free

to contact

Avatar
Avatar
Avatar

Anastasiia Melnikova

Anastasiia Melnikova

Discuss your ideas

Let’s connect and see how we can bring your vision to life.

See LinkedIn

See LinkedIn

Icon
Icon

See LinkedIn

Icon
Icon

Do you prefer email?

anastmel.work@gmail.com

Copy Icon
Copied Icon

Copied

BG Image

Winston Churchill once said:

“A pessimist sees the difficulty in every opportunity; an optimist sees the opportunity in every difficulty.”

That’s the mindset I bring to every project - finding where difficulty hides value and turning it into strategy.

© 2025 All rights reserved

BG Image
Vector

© 2025 All rights reserved

Winston Churchill once said:

“A pessimist sees the difficulty in every opportunity; an optimist sees the opportunity in every difficulty.”


That’s the mindset I bring to every project - finding where difficulty hides value and turning it into strategy.

BG Image
Vector

© 2025 All rights reserved

Winston Churchill once said:

“A pessimist sees the difficulty in every opportunity; an optimist sees the opportunity in every difficulty.”


That’s the mindset I bring to every project - finding where difficulty hides value and turning it into strategy.

BG Image
Vector

Create a free website with Framer, the website builder loved by startups, designers and agencies.